StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 0.4 %

AKTX stock opened at $1.21 on Tuesday. The business’s 50-day moving average price is $1.27 and its 200-day moving average price is $2.52. Akari Therapeutics has a twelve month low of $0.90 and a twelve month high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.